Patents by Inventor Yuya Oguro

Yuya Oguro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10323026
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 18, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shuhei Ikeda, Hideyuki Sugiyama, Jumpei Aida, Hidekazu Tokuhara, Tomohiro Okawa, Yuya Oguro, Minoru Nakamura, Masataka Murakami
  • Publication number: 20190125728
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: March 30, 2017
    Publication date: May 2, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shuhei IKEDA, Hideyuki SUGIYAMA, Jumpei AIDA, Hidekazu TOKUHARA, Tomohiro OKAWA, Yuya OGURO, Minoru NAKAMURA, Masataka MURAKAMI
  • Patent number: 10131653
    Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 20, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Taku Kamei, Yasuyoshi Arikawa, Tomohiro Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Takashi Miki, Jinichi Yonemori, Yuya Oguro, Takahiro Sugimoto, Masaki Seto, Goushi Nishida, Makoto Kamata, Hiroshi Imoto
  • Publication number: 20180155333
    Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: April 22, 2016
    Publication date: June 7, 2018
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Taku KAMEI, Yasuyoshi ARIKAWA, Tomohiro OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Takashi MIKI, Jinichi YONEMORI, Yuya OGURO, Takahiro SUGIMOTO, Masaki SETO, Goushi NISHIDA, Makoto KAMATA, Hiroshi IMOTO
  • Publication number: 20170283406
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shuhei Ikeda, Hideyuki SUGIYAMA, Jumpei AIDA, Hidekazu TOKUHARA, Tomohiro OKAWA, Yuya OGURO, Minoru NAKAMURA, Masataka MURAKAMI
  • Publication number: 20170209452
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Application
    Filed: April 11, 2017
    Publication date: July 27, 2017
    Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
  • Patent number: 9655900
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 23, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa
  • Publication number: 20160310494
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Application
    Filed: June 8, 2016
    Publication date: October 27, 2016
    Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
  • Patent number: 9388195
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 12, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa
  • Publication number: 20150158882
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 11, 2015
    Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
  • Patent number: 8933069
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: January 13, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Misaki Homma, Yuya Oguro
  • Publication number: 20140235615
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Application
    Filed: March 24, 2014
    Publication date: August 21, 2014
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
  • Publication number: 20140228352
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Application
    Filed: March 24, 2014
    Publication date: August 14, 2014
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Misaki HOMMA, Toru MIYAZAKI, Yuya OGURO, Osamu KURASAWA
  • Patent number: 8691828
    Abstract: The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: April 8, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuya Oguro, Osamu Kurasawa
  • Patent number: 8399449
    Abstract: The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention provides a compound represented by the formula (I) wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR1 (R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R2 is carbamoyl optionally having substituent(s); and R3 is hydroxy optionally having substituent(s), or a salt thereof.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: March 19, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nobuhiro Fujii, Yuya Oguro, Satoshi Sasaki, Shigeru Kondo
  • Publication number: 20130029969
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Application
    Filed: February 16, 2011
    Publication date: January 31, 2013
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa
  • Patent number: 8304557
    Abstract: A compound represented by the formula (I): wherein Z1, Z2, Z3 and Z4 are the following combination, (Z1,Z2,Z3,Z4)=(CR4,N,CR5,C), (N,N,CR5,C), (N,C,CR5,N), (S,C,CR5,C) or (S,C,N,C); R1 and R2 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R3 is an amino optionally having substituent(s); R4 and R5 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R3 and R4 optionally form a ring optionally having substituent(s); and a group represented by the formula is a cyclic group optionally having substituent(s), or a salt thereof.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: November 6, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuya Oguro, Shinichi Imamura
  • Patent number: 8217176
    Abstract: The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention provides a compound represented by the formula wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR1 (R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R2 is carbamoyl optionally having substituent(s); and R3 is hydroxy optionally having substituent(s), or a salt thereof.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: July 10, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Yuya Oguro
  • Publication number: 20120040981
    Abstract: The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Application
    Filed: March 4, 2010
    Publication date: February 16, 2012
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yuya Oguro, Osamu Kurasawa
  • Publication number: 20110034469
    Abstract: The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention shows a strong IAP antagonistic activity.
    Type: Application
    Filed: August 3, 2010
    Publication date: February 10, 2011
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Kentaro HASHIMOTO, Tomoyasu ISHIKAWA, Yuya OGURO